AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

📰

Oral cavity cancer: the latest breakthroughs

Everything that changed in the last year, from three public sources: phase 3 trials that posted their results, papers in the leading medical and cancer journals, and US drug labels that were updated. Refreshed every week.

🤖

What changed

Written by AI from the evidence below, every point cited

AI reads the results, papers and label updates below and explains what changed and why it matters, citing each source. It is shared with everyone.

🏁

Phase 3 results posted

The large trials that decide new standard treatments · ClinicalTrials.gov
Conventional Prophylactic Oral Dexamethasone vs Short-course IV Dexamethasone in Paclitaxel HypersensitivityNCT03598426 · results posted 2026-06-09 · Loma Linda University · 90 people · tests Dexamethasone A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)NCT05456191 · results posted 2026-05-27 · Novartis Pharmaceuticals · 568 people · tests Asciminib, Nilotinib Evaluation in the Treatment of Neuropathic Pain Post Breast SurgeryNCT03794388 · results posted 2026-05-05 · Institut Cancerologie de l'Ouest · 140 people · tests Capsaicin, Pregabalin Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With MyelofibrosisNCT04472598 · results posted 2026-03-23 · AbbVie · 252 people · tests Placebo for Navitoclax, Ruxolitinib, Navitoclax Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)NCT05386550 · results posted 2026-02-19 · EMD Serono Research & Development Institute, Inc. · 166 people · tests Xevinapant, IMRT, Placebo LUX-Head&Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based ChemotherapyNCT01856478 · results posted 2026-01-12 · Boehringer Ingelheim · 340 people · tests Methotrexate, Afatinib Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled SeizuresNCT04485104 · results posted 2025-10-31 · Jazz Pharmaceuticals · 3 people · tests GWP42003-P
🏛️

US drug labels updated

A label changes when a new use, dose or warning is approved · openFDA

No label updates found.

An update is not always a new approval — open the label to see what changed.

Want these every week? Follow oral cavity cancer and get a note on your phone with the new trials and papers.

🔔 Follow oral cavity cancer
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy